Page 53 - textbook5chapters
P. 53
Technique of Intraperitoneal Chemotherapy: Normothermic and Hyperthermic 1305
Conclusion 10. Speyer JL, Myers CE. The use of peritoneal dialysis for
delivery of chemotherapy to intraperitoneal malignancies.
Delivery of chemotherapeutic agents into the peritoneal Recent Results Cancer Res 1980; 74:264-269.
cavity has an important and emerging role to play in the
treatment of epithelial ovarian cancer. This chapter has 11. Tenckhoff H, Schechter H. A bacteriologically safe
described some of the current techniques of delivery peritoneal access device. Trans Am Soc Artif Intern Organs
of intraperitoneal chemotherapy. These techniques 1968; 14:181-187.
are straightforward but only continued research will
enable continued improvements in their reliability and 12. Pfeifle E. Totally implantable system for peritoneal access. J
minimization of associated morbidity. Clin Oncol1984; 2:1277-1280.
Acknowledgements 13. Lesnock JL, Richard SD, Zorn KK, et al. Completion of
intraperitoneal chemotherapy in advanced ovarian cancer
I am indebted to the assistance of Arlan F. Fuller, MD in and catheter-related complications. Gynecol Oncol 2010;
providing photographs for the description of his technique 116: 345-350.
for laparoscopic placement of an intraperitoneal port and
Jesus Esquivel, MD for his input on HIPEC. 14. Ivy JJ, Geller M, Pierson SM, et al. Outcomes associated
with different intraperitoneal chemotherapy delivery
References systems in advanced ovarian carcinoma: a single
institution’s experience. Gynecol Oncol 2009;114:420-423
1. Dedrick RL, Myers CE, Bungay PM, et al. Pharmacokinetic
rationale for peritoneal drug administration in the treatment 15. Pendergrass M, Gordinier ME, Parker LP, et al. Retraction
of ovarian cancer. Cancer Treat Rep 1978; 62:1-11 of an intraperitoneal chemotherapy port: a case report and
literature review. Int J Gynecol Cancer 2007;17 (5):1131-
2. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal 1133.
cisplatin plus intravenous cyclophosphamide versus
intravenous cisplatin plus intravenous cyclophosphamide 16. Walker JL. Intraperitoneal Chemotherapy: Technique
for stage III ovarian cancer. N Engl J Med 1996;335: 1950- and Complications. In: Helm CW,Edwards RP. Eds
1955 Intraperitoneal Cancer Therapy. Totowa, NJ: Humana
Press, 2007: 55-69.
3. Markman M, Bundy BN, Alberts DS, et al. Phase III trial of
standard-dose intravenous cisplatin plus paclitaxel versus 17. Liou WS, Teng NN, Chan JK. A Modified Technique for
moderately high-dose carboplatin followed by intravenous Insertion of Intraperitoneal Port for Chemotherapy. J Surg
paclitaxel and intraperitoneal cisplatin in small-volume Oncol 2005;90 (4) :247-248
stage III ovarian carcinoma: an intergroup study of the
Gynecologic Oncology Group, Southwestern Oncology 18. Robinson WR, Beyer J. Factors Affecting the Completion
Group, and Eastern Cooperative Oncology Group. J Clin of Intraperitoneal Chemotherapy in Women With Ovarian
Oncol 2001;19: 1001-1007 Cancer. Int J Gynecol Cancer 2010; 20 (1):70-74.
4. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal 19. Sakuragi N, Nakajima A, Nomura E, et al. Complications
cisplatin and paclitaxel in ovarian cancer. N Engl J Med Relating to Intraperitoneal Administration of Cisplatin or
2006; 354:34-43 Carboplatin for Ovarian Carcinoma. Gynecol Oncol 2000;
79: 420-423.
5. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal
catheter outcomes in a phase III trial of intravenous 20. Jaka RC, Somashekhar SP, Zaveri SS, et al. Intraperitoneal
versus intraperitoneal chemotherapy in optimal stage III Chemotherapy for Epithelial Ovarian Cancer – Single
and primary peritoneal cancer: A Gynecologic Oncology Center Experience. Indian J Surg Oncol 2012; 3(3):262–
Group study. Gynecol Oncol 2006;100:27-32 266
6. Wright AA, Cronin A, Milne DE, et al. Use and Effectiveness 21. Helm CW. The role of hyperthermic intraperitoneal
of Intraperitoneal Chemotherapy for Treatment of Ovarian chemotherapy (HIPEC) in ovarian cancer. Oncologist
Cancer J Clin Oncol 2015; 33:2841-2847 2009; 14: 683-694.
7. Tewari K, Java JJ, Salani R, et al. Long-Term Survival 22. Muller M, Cherel M, Dupre PF, et al. Cytotoxic effect of
Advantage and Prognostic Factors Associated With hyperthermia and chemotherapy with platinum salt on
Intraperitoneal Chemotherapy Treatment in Advanced ovarian cancer cells: results of an in vitro study. Eur Surg
Ovarian Cancer: A Gynecologic Oncology Group Study. J Res 2011; 46: 139–47.
Clin Oncol 2015; 33: 1460-1466
23. Zivanovic O, Abramian A, Kullmann M, et al. HIPEC ROC
8. Bookman MA, Brady MF. Intraperitoneal Chemotherapy: I: a phase I study of cisplatin administered as hyperthermic
Long-Term Outcomes Revive a Long-Running Debate. J intraoperative intraperitoneal chemoperfusion followed by
Clin Oncol 2015; 33 (13): 1424-1426 postoperative intravenous platinum-based chemotherapy
in patients with platinum sensitive recurrent epithelial
9. Jaaback K, Johnson N. Intraperitoneal chemotherapy ovarian cancer. Int J Cancer 2014: 136: 699–708.
for the initial management of primary epithelial ovarian
cancer. Cochrane Database Syst Rev 2006; (1):CD005340. 24. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery
Review. Update in: Cochrane Database Syst Rev 2011; system for intraperitoneal hyperthermic chemotherapy.
(11):CD005340. Cancer Res 1980; 40: 256-260.
25. Loggie BW, Sterchi JM, Rogers AT, et al. Intraperitoneal
hyperthermic chemotherapy for advanced gastrointestinal
and ovarian cancers. Reg Cancer Treat 1994;2:78-81.
26. Spiliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery
and HIPEC in recurrent epithelial ovarian cancer: a
